Sarasota, Florida (PRWEB) April 20, 2012
Rapid Pathogen Screening, Inc. (RPS®), an emerging leader in point-of-care diagnostic testing, today announced that Douglas W. Berg has been appointed to its Board of Directors, effective immediately. The knowledge and skills that Mr. Berg brings from the point-of-care diagnostics and healthcare services field expands the breadth and expertise of the RPS Board.
Mr. Berg’s election increases the RPS Board to seven directors, three of whom are independent directors.
Throughout his notable career, Mr. Berg has held CEO or senior leadership positions at companies including Plus Diagnostics, Isensix, Quest Diagnostics, and Dade Behring/Baxter International/American Hospital Supply Corporation.
“Doug has been a driving force behind the growth and development of several companies during his impressive career in the diagnostics industry,” said Robert Sambursky, MD, president, chief medical officer, and executive chairman of RPS. “He is known throughout the industry and brings a wealth of diagnostic experience, a wide network of contacts, and a shared passion to help RPS realize its vision to become the premier global point-of-care diagnostic business.”
“RPS has done an incredible job in developing a unique technology platform that has a wide range of differentiated applications in rapid, point-of-care testing and will leapfrog current methods,” said Mr. Berg. “I look forward to working with the RPS Board to help the company provide physicians and their patients with novel diagnostic tests that are faster, more accurate, and better able to address today’s challenges of delivering real-time and cost-effective patient care.”
Mr. Berg is also Chairman of the Board at MedTest DX and an Operating Partner at Shore Capital Partners.
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS®) is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment. For more information on RPS or its products, visit RPSdetectors.com.
# # #
For additional information, contact:
Laura Lovejoy, Strategic Marketing Manager, RPS, 941.556.1864, lovejoy(at)rpsdetectors(dot)com